Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results And Host Webcast on May 7, 2024
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results And Host Webcast on May 7, 2024
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets.
賓夕法尼亞州康舍霍肯，2024年4月23日（GLOBE NEWSWIRE）——Madrigal Pharmicals, Inc.（納斯達克股票代碼：MDGL）今天宣佈，將在2024年5月7日星期二在美國金融市場開放之前發佈其2024年第一季度財務業績。
Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
宣佈之後，Madrigal的管理層將在美國東部時間上午8點主持網絡直播，以審查公司的財務和經營業績。
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
網絡直播可在Madrigal Pharmicals的 “投資者關係” 部分觀看 網站。爲確保及時連接，建議參與者在預定網絡直播前至少 15 分鐘註冊。
The webcast will be available approximately two hours after the live webcast.
網絡直播將在網絡直播結束大約兩小時後播出。
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
關於 Madrigal 製藥
Madrigal Pharmaceuticals, Inc.（納斯達克股票代碼：MDGL）是一家生物製藥公司，致力於爲非酒精性脂肪肝炎（NASH）提供新療法，這是一種尚未得到滿足的醫療需求的肝臟疾病。Madrigal的藥物Rezdifra（resmetirom）是一種每天一次的口服、肝臟定向的THR-β激動劑，旨在靶向NASH的關鍵根本原因。欲了解更多信息，請訪問 www.madrigalpharma.com。
Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., [email protected]
投資者聯繫人
蒂娜·文圖拉，Madrigal Pharmicals, Inc. [電子郵件保護]
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., [email protected]
媒體聯繫人
克里斯托弗·弗雷茨，Madrigal Pharmicals, Inc. [電子郵件保護]
Source: Madrigal Pharmaceuticals, Inc.
來源：Madrigal Pharmicals, Inc.
譯文內容由第三人軟體翻譯。